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Summary The correlation between prolactin (PRLR) and oestrogen (ER) or progesterone receptors (PgR) in
breast cancer and a possible prognostic significance of PRLR at 10 year follow-up have been investigated in
the Naples (GUN) adjuvant trial. A total of 308 pre- and post-menopausal patients with early breast cancer,
who entered the trial from 1 February 1978 to 31 December 1983, received randomly Tamoxifen (TM), 30 mg
per die for 2 years, or no therapy. PRLR status was known in 229 (74.3%) patients. Values of specific binding
less than 1% were considered negative. PRLR was positive in 75/229 (32.8%). ER was assayed in 210/229
(91.7%) patients and PgR in 188/229 (82.1%). No significant correlation, by the Spearman test, was found
between PRLR and ER or PgR, while ER status was highly interrelated with PgR status. By the Cox model
no evidence of an independent prognostic role of PRLR on disease-free survival (DFS) was observed, nor an
interaction between PRLR and adjuvant treatment with TM was found.
The growth and regression of breast cancer have been known
to be influenced by steroid and peptide hormones, including
oestrogens, progesterone and prolactin (Lippman et al., 1976;
Lippman, 1981; Dao et al., 1982; Kelly et al., 1978; Naga-
sawa, 1979; Welsch, 1985). This observation has generated a
great deal of hormone receptor research in an attempt to
elucidate the endocrine control mechanisms operative in
breast cancer. The question of the clinical relevance of pro-
lactin receptors has been addressed by several studies with
conflicting results either when a relationship has been sought
between steroid receptors and PRLR (Holdaway & Friesen,
1977; Pearson et al., 1978; Thorpe & Daehnfeldt, 1980; Rae-
Venter et al., 1981; Murphy et al., 1984; Bonneterre et al.,
1986; Ben-David et al., 1988b) or when the prognostic role of
the PRLR has been investigated (Waseda et al., 1985; Bonne-
terre et al., 1987).
In 1978 the study Group of the University of Naples
(GUN) promoted a randomised clinical trial to assess the
effectiveness of adjuvant Tamoxifen in preventing relapse in
operable breast cancer (Bianco et al., 1988). In this study,
unlike other adjuvant trials, oestrogen, progesterone and pro-
lactin receptors were assayed in the same tumour specimen in
most patients. The presence and the concentration of oest-
rogen and progesterone receptors were both significantly
related to the length of DFS in TM treated group but not in
controls.
The major scope of the present report is to investigate the
correlation of PRLR with ER and PgR and to define its
prognostic role in primary breast cancer at 10 year follow-up.
Materials and methods
Receptor assay
Fragments of tumour tissue were obtained from the oper-
ating room and frozen immediately after mastectomy in
liquid nitrogen, where they kept stored for up to 2 weeks
before processing.
For PRLR determination, microsomal membranes from
229 patients were prepared by differential centrifugation
according to Shiu et al. (1973). The resulting pellets were
resuspended in 25 mM Tris-HCI, 10 mM MgCI2, pH 7.6, and
stored for about a month in liquid nitrogen until assayed for
protein content determinations (Hartree, 1972) and for bind-
ing studies (Kelly et al., 1975). Ovine prolactin (oPRL; NIH
PS-10) was iodinated by the lactoperoxidase procedure
(Frantz & Turkington, 1972) and purified by Sephadex G-
100 chromatography. The specific activity of '25I-oPRL was
160 ± 8.5 tCi Ag-'. Each membrane preparation (0.3 mg pro-
tein) was incubated in triplicate with approximately 10'
c.p.m. of 251I-oPRL in a final volume of 0.3 ml assay buffer
(25 mM Tris-HCl, 10mM MgCI2, 1% bovine serum albumin,
pH 7.4). Similar duplicate incubations for each membrane
sample containing 1 Lg of unlabelled o-PRL were used for
non-specific binding determination. The incubations were
performed at room temperature for 16 h and were stopped
by the addition of 3 ml of ice cold buffer. Bound and free
'251I-oPRL were separated by low-speed centrifugation; the
supernatants were decanted and the radioactivity bound to
the membranes was counted in a Packard gamma counter.
The specific binding was calculated by subtracting the mean
of the two non-specific binding measurement from each of
the three individual total binding values of the same mem-
brane preparation. Lyophilised liver membranes from preg-
nant rabbits were utilised as control in the PRLR assay. The
intra and inter-assay variation coefficients were respectively
7% and 10%. No significant differences were found between
assays either in the range or in the mean level of PRLR. The
mean of the specific binding was expressed as percentage of
the total counts added to the incubation medium per 0.3 mg
of membrane protein. Values of specific binding less than 1%
were considered negative.
ER as well as PgR were assayed, in a single laboratory,
using the destran coated charcoal technique (McGuire et al.,
1977; Pichon & Milgrom, 1977). Scatchard analysis was per-
formed to quantify the number of binding sites. Specimens
were designated ER- and PgR- if they contained less than
10 fmol of specific binding sites per mg of cytosol protein.
The laboratory performing these receptor determinations
took part in the Quality Control Programme of the National
Research Council of Italy (CNR).
Details ofpatients
Eligible patients were premenopausal node-negative (N-)
and post-menopausal N- and node-positive (N+) women,
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aged less than 80, with stage I-II-III(T3a) operable uni-
lateral breast cancer. Primary treatment consisted of either
radical or modified radical mastectomy. Most patients with
small tumours (Ti) had quadrantectomy followed by radio-
therapy (high voltage) on the residual breast. Complete node
dissection of ipsilateral axilla was done in all patients. Four
to six weeks after surgery the patients were randomly
assigned to receive TM, 30 mg per day, for 2 years or no
further therapy. Entry period was between 1 February 1978
and 31 December 1983. The design of the GUN study is
detailed elsewhere (Bianco et al., 1988). The data of this
study were included in the Early Breast Cancer Triallists'
Collaborative Group Overview on mortality from primary
breast cancer (EBCTCG, 1988).
Out of 308 randomised patients 229 (74.3%) had PRLR
determined. No differences in treatment allocation, age,
nodal and menopausal status were observed between patients
in whom PRLR was assayed and the remaining without
PRLR (Table I). ER was assayed in 210/229 (91.7%) patients
and PgR in 188/229 (82.1%); 175/229 (76.4%) had ER, PgR
and PRLR assayed.
Statistical analysis
DFS was defined as the time from randomisation to when
either recurrent disease was assessed or was suspected and
later confirmed. Failure was any first recurrence, including
contralateral disease and death. The follow-up data for the
analysis were those available as of 31 January 1988.
Association between PRLR and the other categorical vari-
ables was evaluated by the x2 test and x2 for trend with
ordered categories. Mutual relationships between PRLR, ER
and PgR were assessed by Spearman's rank correlation
coefficient. The Kaplan-Meier method (Kaplan & Meier,
1958) was used to estimate DFS. Overall survival was not
analysed because of the limited number of events. Com-
parison between curves was carried out by the Mantel-
Haenszel procedure (Mantel, 1966). The Cox's proportional
hazard regression model (Cox, 1972) was used to estimate the
prognostic significance of PRLR, and PRLR-covariate inter-
actions. Likelihood ratio test, 2[In L(pp)-ln L(P.O)], was
used in order to test the contribution of prolactin receptor to
the model: under the null hypothesis, i.e. all P equal zero, the
difference of log likelihoods under the model with and the
model without k covariates is asymptotically distibuted as a
Table I Characteristics of patients according to PRLR determina-
tion
PRLR
unknown (%) known (%)
(n= 79) (n =229) P
Age 0.38*
<39 5( 6.3) 7( 3.1)
40-49 10 (12.7) 43 (18.8)
50-59 30 (38.0) 88 (38.4)
>60 34 (43.0) 91 (39.7)
Nodal status 0.59*
negative 48 (60.8) 125 (54.6)
1-3 20 (25.3) 63 (27.5)
>4 11 (13.9) 41 (17.9)
Menopausal status 0.59
pre 14 (17.7) 47 (20.5)
post 65 (82.3) 182 (79.5)
Treatment 0.24
TM 33 (41.8) 113 (49.3)
CTL 46 (58.2) 116 (50.7)
ER <0.0001
not assayed 50 (63.3) 19 ( 8.3)
assayed 29 (36.7) 210 (91.7)
PgR <0.0001
not assayed 73 (92.4) 41 (17.9)
assayed 6 ( 7.6) 188 (82.1)
* By x2 for trend.
x2 with k degrees of freedom. The starting model was the one
with relevant prognostic variables as covariates, including
interaction between TM-treatment and ER/PgR status, as
previously reported (Bianco et al., 1988). All probability
values were two-sided.
Results
Distribution of tumours as function of their PRLR levels is
shown in Figure 1. PRLR was positive in 75/229 (32.8%)
patients, whose characteristics are summarised in Table II.
No differences were observed between PRLR positive
(PRLR +) and negative (PRLR -) in age, menopausal and
nodal status and treatment allocation. No significant associa-
tion was found between PRLR and either ER or PgR (P =
0.37 and P = 0.49 respectively) (Table III). Spearman's rank
correlation coefficients were also calculated on the basis of
the hormonal receptors amount (Table IV). No evidence was
observed of a relationship between PRLR and ER or PgR
while a highly significant correlation was found between ER
and PgR.
No differences in DFS were observed between PRLR +
and PRLR - patients (P = 0.67) (Figure 2). The DFS curve
of PRLR unknowns was almost superimposable with those
pertaining to PRLR + and PRLR - patients (data not
shown). Similar results were found in ER + and in ER - as
well as in PgR + and PgR - subgroups or in treated and
untreated patients (data not shown).
The prognostic significance of PRLR and a potential inter-
action with the effects of adjuvant TM-treatment were fur-
ther investigated by adding them up into a Cox regression
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Figure I Distribution of tumours according to PRLR levels (in
percentage of total counts per 0.3 mg of membrane proteins).
S.B. = specific binding.
Table 11 Relationship between PRLR status and patient characteris-
tics
PRLR
(n= 75) (n= 154) P
Age 0.43*
<39 4( 5.3) 3(1.9)
40-49 15 (20.0) 28 (18.2)
50-59 30 (40.0) 58 (37.7)
>60 26 (34.7) 65 (42.2)
Nodal status 0.47*
negative 40 (53.3) 85 (55.2)
1-3 24 (32.0) 39 (25.3)
>4 11 (14.7) 30 (19.5)
Menopausal status 0.89
pre 15 (20.0) 32 (20.8)
post 60 (80.0) 122 (79.2)
Treatment 0.26
TM 41 (54.7) 72 (46.8)
CTL 34 (45.3) 82 (53.2)
* By x2 for trend.
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Table III Relationship between PRLR and steroid receptors
PRLR
+(%M % P*
ER 0.37
<10 29 (42.0) 44 (31.2)
10-99 21 (30.4) 59 (41.8)
>99 19 (27.6) 38 (27.0)
PgR 0.49
<10 34 (59.6) 61 (46.6)
10-99 8 (14.0) 41 (31.3)
>99 15 (26.3) 29 (22.1)
* By x2 for trend.
Table IV Spearman correlation coefficients between PRLR, ER and
PgR
PRLR ER PgR
PRLR I
ER -0.102 1
(P = 0.14)
PgR -0.075 0.501 1
(P= 0.31) (P<0.0001)
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Figure 2 DFS curves according to PRLR status. No difference
was observed between PRLR + ( ) and PRLR - (---).
P = 0.67. Numbers (on the bottom) refer to patients at risk at the
beginning of each year.
model, in which nodal, menopausal and ER/PgR status,
TM-treatment and first order interaction between ER/PgR
status and TM-treatment were entered as covariates. In a
previous report (Bianco et al., 1988), indeed, ER and PgR
were found to affect DFS in treated but not in control
patients. Introduction of PRLR without and with TM-
PRLR interaction into the model did not significantly in-
crease likelihood of the model (Table V), that is prolactin
receptor neither was an independent prognostic factor nor
affected the efficacy of adjuvant therapy with TM.
Discussion
The role of prolactin in the development and growth of
experimental rat and mouse mammary tumours is well estab-
TableV Evaluationofprognostic relevanceofPRLRonDFSwith the
Cox model
Log- Degrees
likeli-hood 2 [In L(Pp)- of
Model (In L) In L(PP,j)] freedom P
Nodal, menopausal -318.8511
and ER/PgR status,
TM treatment,
TM-ER/PgR
interaction
+ PRLR -318.7011 0.72 1 0.39
+ PRLR and -318.3411 1.02 2 0.60
TM-PRLR
interaction
lished (Manni et al., 1977; Costlow et al., 1975; Welsch &
Gribler, 1973), and PRL stimulates the growth of many
human breast cancer cell lines in vitro (Malarkey et al., 1983;
Manni et al., 1986; Biswas & Vonderhaar, 1987). Thus, it has
been hypothesised that PRL, as well as steroids, might be
involved in the growth of human breast cancer.
In parallel, prolactin receptors have been identified in ex-
perimental tumours (Manni et al., 1977; De Sombre et al.,
1976), in cultured cancer cell lines (Shiu et al., 1987) and in
human breast cancer specimens (Holdaway & Friesen, 1977;
Pearson et al., 1978; Thorpe & Daehnfeldt, 1980; Rae-Venter
et al., 1981; Turcot-Lemay & Kelly, 1982; Murphy et al.,
1984; Bonneterre et al., 1986; Ben-David et al., 1988a,b). A
wide range (13-76%) of prolactin receptor positive breast
tumours has been reported in the literature. This ample
variation could be ascribed to the different criteria used to
distinguish between positive and negative receptor tumours,
difference in assay technique or different patient characteris-
tics. Nevertheless, despite the absolute PRLR + percentage
variation, it is relevant that specific prolactin binding has
been demonstrated by all investigators.
PRLR determination, in addition to that of ER and PgR,
might give a more complete picture of the hormone depen-
dence of the breast cancer patients with respect to its possible
prognostic role and relationship with steroid hormone recep-
tors. These were the questions which were raised in our trial.
No significant correlation was found between ER or PgR
and PRLR, while ER status was highly interrelated with PgR
status. These findings are in agreement with the conclusions
reported in the majority of other studies (Holdaway &
Friesen, 1977; Pearson et al., 1978; Thorpe & Daehnfeldt,
1980; Rae-Venter et al., 1981; Ben-David et al., 1988b). The
lack of relationship between PRLR and steroid receptors
suggests that these receptors are independently expressed.
By contrast, a positive correlation between PRLR and
steroid receptors in breast carcinoma was reported only by
Murphy et al. (1984) and Bonneterre et al. (1986). Murphy et
al. observed a significant correlation between ER and PRLR
in cultured human breast cancer cells and in just a low
number of breast tumour biopsies. The study of Bonneterre
et al. (1986) is the largest in the literature. However, looking
at the strength of correlation, the coefficient values, although
statistically significant, are very low, especially those referring
to free PRLR, which are directly comparable with our data
(Spearman correlation= 0.11 for ER and 0.10 for PgR). In
addition, linear correlation values of 0.074 and 0.05 (both
not significant) were observed between free PRLR and ER
and PgR respectively, when only non-zero values of both
receptors were studied. Total PRLR was found to correlate
with ER and PgR only in post-menopausal patients, r values
never being greater than 0.30. On the basis of the previous
considerations it seems reasonable to argue that a positive
correlation between PRLR and steroid receptors, if any, is
very low with a minor biological and clinical relevance.
To our knowledge, the prognostic significance of PRLR
has been evaluated by only two other groups of authors
(Waseda et al., 1985; Bonneterre et al., 1987) in non-con-
trolled clinical studies. Waseda et al. observed a significantly
worse survival in PRLR + than the PRLR - patients. In his
study, however, univariate analysis was performed without
adjusting for other relevant prognostic factors. Bonneterre et
al. reported that PRLR was a significantly favourable prog-
nostic factor for DFS in subgroups of patients and only in
association with steroid receptors. However, these results
were not adjusted for treatment.
In our study at 10 year follow-up there was no evidence of
an independent prognostic role of PRLR on DFS. Further-
more, no interaction was found between the effect of adju-
vant therapy with TM and prolactin receptor. This conclus-
ion confirms previous observation by Pearson et al. (1978) in
advanced breast cancer.
Further studies are needed to investigate the role of PRLR
in predicting for response to PRL suppressing agents, such as
bromocriptine or, more recently, superagonists of somato-
statin (Scambia et al., 1988; Setyono-Han et al., 1987).
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Finally, the lack of correlation between steroid receptors
and PRLR might open new avenues in the treatment of
breast cancer, e.g. the combining of*anti-oestrogens or LH-
RH analogues with bromocriptine or somatostatin
analogues, in order to achieve complete suppression of both
oestrogen and prolactin activity.
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